N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, announced launch of N-of-One PrecisionInsights, a new clinical interpretation solution specifically designed for small gene panels of 15-20 genes.
As organisations introduce more targeted NGS panels with 15-20 genes for molecular profiling in oncology, they continue to need quality clinical interpretation at a very cost effective price for the thousands of variants that are discovered in smaller panels and need to be understood in the context of the specific cancer subtype.
N-of-One PrecisionInsights is a concise, two-page report for each case providing the most recent clinical and scientific evidence specific to the identified genes and variants in the context of the specific cancer sub type. Key attributes include turnaround time of one business day, cost-effective pricing of $65 per report, with a one-time $1,000 implementation, most up-to-date scientific and clinical evidence in the industry. It incorporates NCCN guidelines and relevant therapies.
“Given our leading knowledge base containing many thousands of cases and tens of thousands of variants, N-of-One is able to meet this cost challenge for rapid, quality clinical interpretation of small NGS panels with 15-20 genes,” said Chris Cournoyer, CEO of N-of-One.
“Organisations need to be able to scale for the growing adoption of NGS testing while maintaining quality, currency of relevant evidence, and very rapid turnaround times.”
As with other N-of-One clinical interpretation solutions, N-of-One PrecisionInsights is based on the same foundation of high-quality clinical interpretation:
N-of-One interpretation is specific for each cancer subtype. For example, interpretation of a breast cancer case will address the impact of the detected somatic variants in the context of the specific histolopathology of the breast cancer.
N-of-One’s team of over 30 on-staff PhD scientists and oncologists research and analyse each case to ensure accuracy and actionability. N-of-One’s knowledgebase is recognized as one of the most comprehensive sources of oncology clinical and scientific evidence in the industry.